Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (U01AI138897, 1R01AI120938, 1P30AI094189, U01AI134591)
National Cancer Institute (K23CA177321)
National Institute of Diabetes and Digestive and Kidney Diseases (K24DK101828, K01DK101677)
Received: 27 November 2020
Accepted: 16 February 2021
First Online: 18 March 2021
Ethics approval and consent to participate
: Work to develop and test PROMETHEUS was approved by the Johns Hopkins Medicine Institutional Review Board [IRB00151494]. Written informed consent was obtained for cognitive and pilot testing.
: Not applicable.
: Christine M. Durand has received grant support from Abbvie and GlaxoSmithKline. She serves on a grant review committee for Gilead Sciences. Jeremy Sugarman is a member of Merck KGaA’s Bioethics Advisory Panel and Stem Cell Research Oversight Committee, a member of IQVIA’s Ethics Advisory Panel, a member of Aspen Neurosciences Scientific Advisory Board, consults with Biogen, and has consulted with Portola Pharmaceuticals, Inc., unrelated to the data described in this manuscript. All other authors report no conflicts of interest.